FindTrial
Sign In

Multicenter Cross-Sectional Study on Pharmacotherapeutic Regimens for Clonorchiasis in Guangxi: Focus on Clinical Application Status of Albendazole and Praziquantel

Multicenter Cross-Sectional Study on Pharmacotherapeutic Regimens for Clonorchiasis in Guangxi: Focus on Clinical Application Status of Albendazole and Praziquantel

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116243
Enrollment
Unknown
Registered
2026-01-07
Start date
2026-01-07
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clonorchiasis sinensis

Interventions

Observation group:N/A

Sponsors

The First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Clinically diagnosed with clonorchiasis (Clonorchis sinensis infection/Chinese liver fluke infection). 2.Medical records clearly document receipt of monotherapy or combination therapy with albendazole or praziquantel.

Exclusion criteria

Exclusion criteria: 1.Complicated with other parasitic infections. 2.Severe lack of medical record data, making it impossible to determine the medication regimen.

Design outcomes

Primary

MeasureTime frame
Distribution of drug use, dosage regimens and course selection;—

Secondary

MeasureTime frame
Re - examination status;—

Countries

China

Contacts

Public ContactHongliang Zhang

The First Affiliated Hospital of Guangxi Medical University

277749097@qq.com+86 771 535 6154

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026